Reuters Market Eye - Broader sentiment is expected to be weak in Indian stocks after data showed the current account deficit widened to a record high 6.7 percent of GDP in the October-December quarter.
However, the data, coming out after market hours on Thursday, also showed the balance of payments turned positive.
Still, traders say macro-economic indicators may have bottomed out and point to signs of recovery ahead.
Analysts also feel the recent correction in shares have made valuations more compelling.
Drug makers could be in focus as the Supreme Court is due to decide on April 1 whether Novartis AG's cancer treatment Glivec deserves a patent in the country.
KEY EVENTS/FACTORS TO WATCH:
Mon: March HSBC manufacturing PMI, Feb infrastructure output
- Supreme Court ruling on Novartis' Glivec
- Debt/FX markets closed for banking holiday
(Reporting by Manoj Dharra)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
